Background: Estrogen has played an important role in the development of breast cancer. ER-a PvuII gene polymorphism is in close association with the occurrence risk of breast cancer, but no consensus has been achieved currently.
Introduction
According to the global data statistics on cancer in 2012, breast cancer had become the most common malignancy and the leading cause for cancer-related death in females, and about 1,700,000 had been diagnosed with breast cancer, and 521,900 died of breast cancer annually. [1] In China, new cases with breast cancer account for 15% in females, with morbidity and mortality increasing annually. [2] At present, multiple studies have shown that genetic mutation, menopause status, family history, fertility, alcoholic consumption, smoking, and exposure to estrogen are risk factors for women with breast cancer, and play important roles in the pathogenesis and progression of breast cancer. [3] [4] [5] Estrogens exert great functions in the development and progression of breast cancer, whose effects are mainly mediated by intracellular estrogen receptors (ERs). ER-a and ER-b, 2 types of ER, are important regulators for the actions of estrogens, in which ER-a gene can encode a transcription factor with an estrogen response element (ERE) DNA-binding domain and an estrogen-binding domain. [6] ERa gene, as a steroid hormone receptor gene, is located in chromosome 6 at 6p25.1, and ERa gene mutation can induce cell proliferation, regulate cell apoptosis by affecting protein expression, so as to participate in the development and progression of breast cancer. [7] Multiple single nucleotide polymorphisms (SNPs) in ER-a, as located in intron 1 of ER-a, have been studied in numerous clinical studies and have become one of the hot topics on tumor susceptibility, including rs2234693, also termed as ERa gene PvuII. [8] ER-a PvuII SNPs have found to be associated with numerous carcinoma included prostate cancer, [9] systemic lupus erythematosus, [10] Alzheimer disease, [11] etc. And ER-a PvuII polymorphisms have been verified to be in close connection with tumorigenesis. It has also been found that ER-a PvuII and Xbal polymorphisms are closely related with breast cancer, [12] in which ER-a PvuII polymorphism is proved to play an important role in breast cancer risk in pre-menopausal females . [13] Although the association between ERa gene Pvu II polymorphism and breast cancer susceptibility has been extensively reported currently, there are great differences among study conclusions. Atoum et al [14] did not found any correlation between ERa gene Pvu II polymorphism and breast cancer risk in Jordaneses, but some investigators discovered that there was a significant correlation between ERa gene Pvu II polymorphism and breast cancer risk in Brazilians and Northern Indians and patients with p allele had lower morbidity of breast cancer. [15, 16] Although meta-analysis have been conducted in pre-studies, [13, [17] [18] [19] there are still new literatures on the association between ERa gene Pvu II polymorphism and breast cancer risk published. Considering the timeliness of meta-analysis and to provide a more accurate estimation of the association between ERa gene Pvu II polymorphism and breast cancer susceptibility, an updated meta-analysis on related case-control studies published in Open Access journals was conducted to further determine the association between ERa gene Pvu II polymorphism and breast cancer susceptibility by involving as many data as possible from published studies.
Materials and methods

Literature retrieval
Case-control studies on the association between ERa gene Pvu II polymorphism and breast cancer susceptibility included in medical databases such as PubMed, Embase, China Biomedicine (CBM) database, Wanfang database, VIP database, and China National Knowledge Infrastructure (CNKI) database were retrieved using terms such as "estrogen receptor a," " ERa," "Pvu II," "rs2234693," "polymorphism," "single nucleotide polymorphism," "variation," "breast carcinoma," "breast cancer," and "BC." Simultaneously, references in corresponding literatures included in above databases were retrieved artificially based on the title of the literatures in order to screen more applicable literatures.
Inclusion and exclusion criteria
Inclusion criteria included studies published in English or Chinese language before September 1, 2017; case-control studies; studies that enrolled healthy populations in the control group; studies with full texts; studies on the distribution frequency of ERa gene Pvu II or studies that provided corresponding odds ratio (OR) value with clearly described data; studies focused on the association between breast cancer risk and ERa gene Pvu II polymorphism. Exclusion criteria included studies with incomplete data; studies in which patients with fibroadenoma of breast or nonbreast cancer were selected as study subjects; studies that focused on exploring the association between gene polymorphism and other factors such as disease progression, disease severity, phenotype modification, sensitivity to clinical treatment, or survival, etc; studies on family association; and studies in which systematic reviews or meta-analysis were also excluded. In overlapping studies, those with large sample size were selected.
Data extraction
In this study, the ERa gene Pvu II polymorphism in enrolled population was set as the primary index. Two researchers were assigned to collect literatures independently based on above inclusion criteria, exclusion criteria, and data extraction criteria, with following variables extracted from each study: the year of publication, name of the first author, source of the controls, ethnicity of enrolled population, gene detection method, and phenotype distribution data, etc. The disagreement in data extraction should be resolved by discussion or a third-party researcher when necessary. The data involving different ethnicities should be extracted independently based on ethnicity. The ethnicities included in this study contained Caucasians, Asians, and others.
Quality assessment
The quality of the case-control studies enrolled in this study was assessed by 2 investigators using Newcastle-Ottawa Scale (NOS). Primary contents to be assessed include selection of study subjects (4 scores in total); inter-group comparability (2 scores in total); exposure factors or outcomes (3 scores in total). Low-quality studies: 0 to 4 points; high-quality studies: 5 to 9 points.
Statistical data analysis
STATA 14.0 software was used to analyze the extracted data. Hardy-Weinberg equilibrium (HWE) analysis was performed using x 2 test. Allele model, homozygous model, dominant model, and recessive model were used, and pooled OR values and 95% confidence intervals (95% CIs) were used to assess the association between ERa gene Pvu II polymorphism and breast cancer susceptibility. The heterogeneity was assessed by Q and I 2 statistics. There was no heterogeneity if P > .1 or I 2 < 50%, for which fixed-effect model (Mantel-Haenszel method) was used. There was heterogeneity if P < .1 and I 2 > 50%, for which random-effect (DerSimonian Laird) model was used for analysis. Subgroup analysis was performed on the basis of ethnicity and source of controls. Funnel plot was applied to detect whether there was publication bias in the enrolled literatures. There was publication bias if the funnel plot was asymmetric. Egger test was adopted to test the severity of publication bias. The stability of results was analyzed and assessed by sensitivity analysis. Twotailed test was applied, with a P < .05 level of significance.
Results
General information of enrolled literatures
A total of 409 articles were retrieved using the keywords, as shown in Fig. 1 . A total of 367 articles were excluded according to the titles and abstracts, among which 211 were significantly irrelevant, 146 were overlapped, 5 were reviews, and 5 were animal or cell experiments; 7 were about meta-analysis and 9 were not related with Pvu II polymorphisms. Finally, 26 full-text articles with detailed study information enrolling 15,360 cases and 26,423 controls were obtained. The primary 97: 17 Medicine information of studies enrolled in this meta-analysis is summarized in Table 1 . 
Meta-analysis results
The meta-analysis results indicated that a significant association between ERa gene Pvu II polymorphism and the decrease of breast cancer risk was found in allele model, homozygous model, and recessive model (C vs T, OR = 0.962, 95% CI = 0.933-0.992, P = .012; CC vs TT, OR = 0.911, 95% CI = 0.856-0.969, P = .003; CC vs TT/CT, OR = 0.923, 95% CI = 0.874-0.975, P = .004) rather than in dominant model (CC/CT vs TT, OR = 0.970, 95% CI = 0.927-1.015, P = .187), as shown in Fig. 2 . Subgroup analysis was conducted based on ethnicity, and the results suggested that in Asians, a significant association between ERa gene Pvu II polymorphism and the decrease of Table 2 .
Analysis of publication bias and sensitivity
Funnel plot and Egger test were used to analyze the publication bias in above 4 models, but no significant publication bias was found, as shown in Fig. 3A and B. The Egger results were C vs T: t = 0.71, P = .487; CC vs TT: t = 0.56, P = .582; CC/CT vs TT: t = 0.74, P = .465; CC vs TT/CT: t = 0.53, P = .601. The sensitivity analysis also indicated stable results, as shown in Fig. 3C .
Discussion
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China At present, genetic polymorphism has become one of the hot topics in the studies on risk factors of breast cancer. Although the association between ERa gene PvuII polymorphism and breast cancer risk has been reported widely, the conclusions vary in different studies due to the difference of study design, study methods, regions and ethnicities, etc. Multiple studies have reported that patients carried with T allele exhibit relatively low morbidity of breast cancer. [15, 16, 22] However, Cai et al [40] pointed out that TT could increase the risk of breast cancer. Some researchers believed that there was no association between ERa gene PvuII polymorphism and breast cancer risk. [14, 20] Therefore, this study mainly analyzed 26 studies on the association between ERa gene Pvu II polymorphism and breast cancer susceptibility through meta-analysis, and obtained more accurate and objective conclusion by reducing randomization error and increasing the power of test.
This meta-analysis mainly enrolled 15,360 cases and 26,423 controls, and the results revealed that the breast cancer susceptibility decreased significantly in people carried with ERa gene Pvu II CC genotype or C allele, which was similar to the conclusions of Lu et al, [13] Zhang et al, [17] and Li et al. [18] However, how ERa gene intron Pvu II affect the receptor function to participate in the pathogenesis of breast cancer is still unclear. A study has shown that Pvu IIare near to ERa gene promotor, which may impact the stability of other genes or mRNA transcription so as to affect the expressions of other genes. [41] In addition, some introns may regulate the expression levels of proteins by regulating the gene transcription. [42] Another study has reported that compared with T allele, C allele could produce the function-binding site of transcription factor B-myb, so as to influence the transcription level of ERa gene. [43] Liu et al [44] reported that ERa played an important role in the active regulation of p53, as the combination of ERa and p53 could inhibit the function of wild p53 so that the wild p53could not suppress the tumor growth and metastasis of ERa-positive breast cancer. However, whether CC phenotype participates in the development and progression of breast cancer via these pathways needs to be further studied and verified. Factors such as ethnicity, region, living environment, and age exert certain function in the development and progression of breast cancer. We found in the subgroup analysis based on ethnicity that there was significant association between ERa gene Pvu II polymorphism and the decrease of breast cancer risk in Asians rather than in Caucasians. Lu et al, [13] Zhang et al, [17] and Li et al [18] also reported the significant association between ERa gene Pvu II polymorphism and the decrease of breast cancer risk in Asians. This difference might be caused by the genetic heterogeneity among different ethnicities, or was connected with interaction between genes, the linkage disequilibrium between SNPs sites, regions, living environment, and lifestyles. There are significant differences in the distribution of Pvu II polymorphism in European, Asian, and African populations. Most genetic phenomenon, such as natural selection, mutation, random shift, genetic hitchhiking, or gene flow, can cause large amount of linkage disequilibrium, which may also occur in different ethnicities or populations. In addition, intergenetic interaction and gene-environment interaction may also trigger distinct contributions of gene to tumorigenesis among different ethnicities. [45] The difference in selection of controls may lead to betweenstudy heterogeneity. Therefore, this study conducted a subgroup analysis based on the source of controls, and the results illustrated that in population-based subgroup rather than hospital-based subgroup, there was a significant association between ERa gene Pvu II polymorphism and the decrease of breast cancer risk. The morbidity of breast cancer may increase greatly in hospital-based controls in the future, which may trigger significant difference between different subgroups. However, Li et al [13] did not show that the association between Pvu II polymorphism and breast cancer risk was in any association with the source of controls.
Although researchers in pre-study have reported the association between ERa gene Pvu II polymorphism and breast cancer risk, [13, 18, 24] this study was more in the number of articles enrolled and larger in sample size, which comparatively reduced the influence of contingency on the results of meta-analysis. Therefore, the conclusions of this study were more persuasive and accurate.
However, this study also had some limitations described as follows. First, the studies enrolled lacked of data of family history, smoking, alcoholic consumption, age, and other environmental exposure factors; therefore, its OR values were nonadjusted data. Second, stratified analysis was not conducted based on pathological patterns, as the studies enrolled lacked of complete data on pathological patterns. Third, this study did not analyze the influence of interaction of different genes and interaction of genes with environment on the association of gene polymorphism and breast cancer risk. Fourth, the selection bias of controls by researchers in studies could not be avoided. Therefore, a comprehensive analysis of larger sample size and sample information is needed in the future so as to obtain more accurate conclusion on the association between ERa gene Pvu II polymorphism and breast cancer susceptibility. In conclusion, this meta-analysis has found that ERa gene Pvu II polymorphism has participated in the development and progression of breast cancer. However, larger sample size, more accurate sample information, and more strict and reasonable study design are needed in the future to comprehensively verify the association between ERa gene Pvu II polymorphism and breast cancer risk.
